CTRX, STJ, CI, TMO And BAX, Pushing Health Services Industry Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is down 0.37. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 1.34, and Varian Medical Systems ( VAR), down 1.29.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Catamaran ( CTRX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Catamaran is down $0.67 (-1.4%) to $47.90 on average volume Thus far, 973,000 shares of Catamaran exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $47.51-$48.25 after having opened the day at $48.17 as compared to the previous trading day's close of $48.57.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $10.4 billion and is part of the health care sector. The company has a P/E ratio of 68.1, above the S&P 500 P/E ratio of 17.7. Shares are up 7.0% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Catamaran Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, St Jude Medical ( STJ) is down $0.43 (-0.9%) to $45.27 on light volume Thus far, 860,735 shares of St Jude Medical exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $45.10-$45.62 after having opened the day at $45.41 as compared to the previous trading day's close of $45.70.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $13.3 billion and is part of the health care sector. The company has a P/E ratio of 18.6, above the S&P 500 P/E ratio of 17.7. Shares are up 26.5% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full St Jude Medical Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Cigna ( CI) is down $0.63 (-0.9%) to $67.33 on light volume Thus far, 641,304 shares of Cigna exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $66.88-$68.02 after having opened the day at $67.52 as compared to the previous trading day's close of $67.96.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $19.3 billion and is part of the health care sector. The company has a P/E ratio of 14.9, below the S&P 500 P/E ratio of 17.7. Shares are up 26.4% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cigna Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.91 (-1.1%) to $85.37 on average volume Thus far, 991,031 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $84.98-$85.85 after having opened the day at $85.72 as compared to the previous trading day's close of $86.28.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $31.4 billion and is part of the health care sector. The company has a P/E ratio of 24.2, above the S&P 500 P/E ratio of 17.7. Shares are up 35.3% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Baxter International ( BAX) is down $0.58 (-0.8%) to $71.72 on average volume Thus far, 1.8 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $71.55-$72.15 after having opened the day at $71.85 as compared to the previous trading day's close of $72.30.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.6 billion and is part of the health care sector. The company has a P/E ratio of 17.6, below the S&P 500 P/E ratio of 17.7. Shares are up 9.6% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

As Cyberattacks Rise, This Is Why CEOs Might Want to Prepare for the Worst and Buy Bitcoins

As Cyberattacks Rise, This Is Why CEOs Might Want to Prepare for the Worst and Buy Bitcoins

The Price of Bitcoin May Be Rising Because of This One Factor

The Price of Bitcoin May Be Rising Because of This One Factor

Crude Surge Marches Dow to Near Record Close

Crude Surge Marches Dow to Near Record Close

Analysts' Actions -- Cirrus Logic, Ford, Kinder Morgan, PayPal and More

Analysts' Actions -- Cirrus Logic, Ford, Kinder Morgan, PayPal and More

Verizon Nixing Discounted Phones May Turn Into a Self-Inflicted Wound

Verizon Nixing Discounted Phones May Turn Into a Self-Inflicted Wound